FDA has approved Sarclisa (isatuximab-irfc) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.
Homologous recombination deficiency tests are used routinely in the clinic to determine which patients get PARP inhibitors.
